Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial.
Lauren L O'MahoneyGareth DunseathRachel ChurmMel HolmesChristine BoeschAntonios Stavropoulos-KalinoglouRamzi A AjjanKaren M BirchNicolas M OrsiGeorgia MappaOliver J PriceMatthew D CampbellPublished in: Cardiovascular diabetology (2020)
This study indicates that daily high-dose-bolus of n-3PUFA supplementation for 6-months does not improve vascular health, glucose homeostasis, or metabolic parameters in subjects with T1D. The findings from this preliminary RCT do not support the use of therapeutic n-3PUFA supplementation in the treatment and management of T1D and its associated complications. Trial Registration ISRCTN, ISRCTN40811115. Registered 27 June 2017, http://www.isrctn.com/ISRCTN40811115 .
Keyphrases
- fatty acid
- study protocol
- phase iii
- high dose
- public health
- healthcare
- mental health
- clinical trial
- phase ii
- health information
- randomized controlled trial
- open label
- low dose
- physical activity
- health promotion
- double blind
- blood pressure
- metabolic syndrome
- blood glucose
- stem cell transplantation
- human health
- combination therapy
- risk assessment
- weight loss
- insulin resistance